Statement from Ralph G. Neas, President and CEO, GPhA on FDA Decision on Abuse-Deterrent Formulations of OxyContin

Published Online: Wednesday, April 17, 2013
Follow Pharmacy_Times:
PRESS RELEASE

WASHINGTON, DC (April 17, 2013) — “We share the Agency’s goal of addressing prescription opioid abuse, and using a science-based approach to take on this complex problem. At the same time, we recognize the importance of balancing patient access to medicine with efforts to minimize abuse.

Yesterday’s decision from the FDA provides clear guidance on what is considered an abuse-deterrent formulation for OxyContin, information that GPhA and its member companies have been seeking since 2010.

Along with the draft guidance on abuse-deterrent formulations made available in January, this represents a beginning for other brand and generic manufacturers seeking to create these formulations.

We will continue to work with FDA to make progress on this front, contributing our comments to the public commentary period to hone the standards, and offering our manufacturers’ perspective.

As the science of abuse deterrence evolves, we look forward to making contributions to this new field.”

Related Articles
The Generic Pharmaceutical Association welcomes the FDA’s proposed rule to amend its prescription drug and biological product labeling regulations to require electronic distribution of the prescribing information intended for healthcare professionals.
The Generic Pharmaceutical Association has serious concerns about the unbalanced structure of the Trans-Pacific Partnership agreement in its current form.
GPhA has agreed to support compromise automatic substitution legislation that would allow interchangeable biologics to be automatically substituted at the pharmacy. This step brings millions of Americans closer to the day when they will be able to access safe alternatives to costly biologic medicines. Indeed, Express Scripts projects savings of $250 billion in 10 years should only the 11 likeliest biosimilars enter the market.
Today Reps. Doug Collins (R-Ga.) and Dave Loebsack (D-Iowa) introduced H.R. 5815, The Generic Drug Pricing Fairness Act, which creates greater transparency in how pharmacy benefit managers reimburse pharmacies for generic prescription drugs under Medicare Part D, and the Federal Employees Health Benefits Program. The National Community Pharmacists Association endorsed the bill, which goes further than legislation the same two Congressmen introduced earlier year that has the same remedies, but only applied to Medicare Part D.
Latest Issues
$auto_registration$